Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Safety and PK of Generic Caspofungin in Febrile Neutropenia
NCT03857399Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of caspofungin in fungal infection (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Efficacy evaluation 7 days after drug withdrawal, Peak Plasma Concentration (Cmax) at Day 4 and 2 more. Started Sep 2018; status: completed.
02
Drugs
caspofungin
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT03857399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03857399.